CN114651002A - 肿瘤特异性多肽序列及其应用 - Google Patents

肿瘤特异性多肽序列及其应用 Download PDF

Info

Publication number
CN114651002A
CN114651002A CN201980102087.4A CN201980102087A CN114651002A CN 114651002 A CN114651002 A CN 114651002A CN 201980102087 A CN201980102087 A CN 201980102087A CN 114651002 A CN114651002 A CN 114651002A
Authority
CN
China
Prior art keywords
polypeptide
seq
tumor
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980102087.4A
Other languages
English (en)
Inventor
邱思
李波
李佑平
张乐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genoimmune Therapeutics Co Ltd
Original Assignee
Genoimmune Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoimmune Therapeutics Co Ltd filed Critical Genoimmune Therapeutics Co Ltd
Publication of CN114651002A publication Critical patent/CN114651002A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供了肿瘤特异性多肽序列及其应用。该多肽包括第一肽组中的至少任意一种多肽，还可选择性包括第二肽组中的至少任意一种多肽；第一肽组包括具有SEQ ID NO:1～SEQ IDNO:5所示序列的多肽；第二肽组包括SEQ ID NO:1～SEQ ID NO:5所示序列的衍生肽，该衍生肽包括依次相连的前中和后肽段，中肽段与SEQ ID NO:1～SEQ ID NO:5所示序列具有至少80％以上的同源性，前后肽段的长度之和为14～16个氨基酸。还提供了分离的核酸，构建体，表达载体，药物组合物，抗原呈递细胞，免疫效应细胞，肿瘤疫苗，以及多肽在制备预防或者治疗肿瘤的药物中的用途和治疗肿瘤患者的方法。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980102087.4A 2019-11-07 2019-11-07 肿瘤特异性多肽序列及其应用 Pending CN114651002A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/116164 WO2021087839A1 (zh) 2019-11-07 2019-11-07 肿瘤特异性多肽序列及其应用

Publications (1)

Publication Number Publication Date
CN114651002A true CN114651002A (zh) 2022-06-21

Family

ID=75849465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980102087.4A Pending CN114651002A (zh) 2019-11-07 2019-11-07 肿瘤特异性多肽序列及其应用

Country Status (3)

Country Link
CN (1) CN114651002A (zh)
TW (1) TWI748349B (zh)
WO (1) WO2021087839A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117316273A (zh) * 2023-11-02 2023-12-29 聊城市人民医院 基于图神经网络的肿瘤个体化新抗原多肽筛选方法及装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790224A (zh) * 2016-09-30 2019-05-21 武汉华大吉诺因生物科技有限公司 Cacna1h衍生的肿瘤抗原多肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
ATE439383T1 (de) * 2005-09-20 2009-08-15 Peter Jon Nelson Gewebeinhibitor für metalloproteinasen (timp) gebunden an ein glycosylphosphatidylinositol (gpi-) anker zur behandlung von krebs
DE602005015733D1 (de) * 2005-12-02 2009-09-10 Apceth Gmbh & Co Kg Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration
WO2014193999A2 (en) * 2013-05-28 2014-12-04 Caris Science, Inc. Biomarker methods and compositions
DK3288581T3 (da) * 2015-04-27 2021-01-11 Cancer Research Tech Ltd Fremgangsmåde til behandling af cancer
TW201930340A (zh) * 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN110272874A (zh) * 2018-03-15 2019-09-24 北京卡替医疗技术有限公司 一种包含负载新抗原的b细胞疫苗的免疫细胞药物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790224A (zh) * 2016-09-30 2019-05-21 武汉华大吉诺因生物科技有限公司 Cacna1h衍生的肿瘤抗原多肽及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIANG, Z.D.等: "The common neoantigens in colorectal cancer are predicted and validated to be presented or immunogenic", BIORXIV, pages 1 - 47 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117316273A (zh) * 2023-11-02 2023-12-29 聊城市人民医院 基于图神经网络的肿瘤个体化新抗原多肽筛选方法及装置

Also Published As

Publication number Publication date
TW202118772A (zh) 2021-05-16
TWI748349B (zh) 2021-12-01
WO2021087839A1 (zh) 2021-05-14

Similar Documents

Publication Publication Date Title
TWI838465B (zh) 腫瘤免疫治療多肽及其應用
CN109923121B (zh) 多肽及其应用
CN114650838B (zh) 肿瘤特异性多肽序列及其应用
CN112142837A (zh) 新抗原肽组合物及其在肿瘤免疫治疗药物中的应用
CN110214144B (zh) 多肽及其应用
CN109803978B (zh) 多肽及其应用
CN114651002A (zh) 肿瘤特异性多肽序列及其应用
CN116970058A (zh) 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用
US11612643B2 (en) Col14A1-derived tumor antigen polypeptide and use thereof
US11548925B2 (en) CACNA1H-derived tumor antigen polypeptide and use thereof
CN110167956B (zh) 多肽及其应用
CN109963862B (zh) 多肽及其应用
CN114702569B (zh) Pd-l1相关疫苗及其应用
CN114657158B (zh) Ido1相关疫苗及其应用
CN110191893B (zh) 多肽及其应用
CN109952308B (zh) 多肽及其应用
WO2024138753A1 (zh) 一种hla-a*24:02限制性抗原点替换方法、获得的多肽及其应用
CN110072876B (zh) 多肽及其应用
WO2024138754A1 (zh) 一种hla-a*11:01限制性抗原点替换方法、获得的多肽及其应用
CN110804088A (zh) 巨细胞病毒相关抗原短肽及其应用
CN116948004B (zh) 针对ctnnb1基因h36p突变的肿瘤新抗原多肽及其应用
US6514493B1 (en) cDNA clone for tumor rejection antigen gp110 and tumor peptide vaccine
CN118791626A (zh) 针对kif5b-alk融合基因的肿瘤新抗原多肽及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination